|
|
 | | | |
- close
- close
- close
- close
Stem Cell Therapeutics (SSS) |
QUOTE AND NEWS
Marketwire
Apr 26
Comment
TORONTO, ONTARIO -- (Marketwire) -- 04/26/12 -- Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or the "Company") a life sciences development company of stem cell-related therapeutics, today reported its operational and financial results for
Marketwire
Apr 10
Comment
CALGARY, ALBERTA -- (Marketwire) -- 04/10/12 -- Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or the "Company") has provided a corporate update for its shareholders now available on the investors' page of the Company's website:
Marketwire
Dec 13
Comment
TORONTO, ONTARIO -- (Marketwire) -- 12/13/11 -- Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT") today announced that Dr. John E. Dick, Senior Scientist at Princess Margaret and Toronto General Hospitals, and Dr. Janet Rossant, Senior Scientist
Marketwire
Dec 7
Comment
CALGARY, ALBERTA -- (Marketwire) -- 12/07/11 -- Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) today announced a corporate reorganization to reposition the company as the commercialization partner of choice for stem cell technologies in regenerative
Marketwire
Sep 27
Comment
CALGARY, ALBERTA -- (Marketwire) -- 09/27/11 -- Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the "Company") has posted an investor update on its corporate website - StemCellThera.com. The update includes a letter to shareholders together
Marketwire
Jul 18
Comment
CALGARY, ALBERTA -- (Marketwire) -- 07/18/11 -- Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) today announced the appointment of Dr. Calvin Stiller and Dr. Niclas Stiernholm to the company's Board of Directors as it continues to expand upon the
Marketwire
Jul 12
Comment
CALGARY, ALBERTA -- (Marketwire) -- 07/12/11 -- Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the "Company") announces the oral presentation of traumatic brain injury (TBI) research at the National Neurotrauma Symposium (NNS 2011) in
Marketwire
Apr 28
Comment
CALGARY, ALBERTA -- (Marketwire) -- 04/28/11 -- Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the "Company") is pleased to announce the enrollment of the first patient in the SCT supported Open label Phase IIa traumatic brain injury
Canadian Business
Apr 21
Comment
CALGARY - Stem Cell Therapeutics Corp. (TSXV:SSS) says its annual loss narrowed slightly in fiscal 2010 to $4.46 million.That was down from
FierceBiotech
Dec 1
Comment
> Stem Cell Therapeutics has reported, as per a previous press release dated June 25, 2010, the consulting agreements with Alan Moore (president & CEO) and Allen Davidoff (VP of product development) will expire on December 31, 2010. Davidoff has...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
